Tonix Pharmaceuticals (TNXP) Competitors $0.24 +0.00 (+0.21%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TNXP vs. NLTX, PRQR, ZNTL, CRDF, SLN, CYBN, CGEN, ACRS, GNFT, and LYELShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Neoleukin Therapeutics (NLTX), ProQR Therapeutics (PRQR), Zentalis Pharmaceuticals (ZNTL), Cardiff Oncology (CRDF), Silence Therapeutics (SLN), Cybin (CYBN), Compugen (CGEN), Aclaris Therapeutics (ACRS), Genfit (GNFT), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Neoleukin Therapeutics ProQR Therapeutics Zentalis Pharmaceuticals Cardiff Oncology Silence Therapeutics Cybin Compugen Aclaris Therapeutics Genfit Lyell Immunopharma Neoleukin Therapeutics (NASDAQ:NLTX) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations. Do analysts prefer NLTX or TNXP? Tonix Pharmaceuticals has a consensus target price of $53.50, suggesting a potential upside of 22,617.62%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in NLTX or TNXP? Tonix Pharmaceuticals received 290 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 61.04% of users gave Tonix Pharmaceuticals an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Tonix PharmaceuticalsOutperform Votes34061.04% Underperform Votes21738.96% Which has stronger valuation and earnings, NLTX or TNXP? Neoleukin Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.67Tonix Pharmaceuticals$7.77M5.66-$116.66M-$52.740.00 Does the media favor NLTX or TNXP? In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 1 mentions for Neoleukin Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.06 beat Neoleukin Therapeutics' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neoleukin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of NLTX or TNXP? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, NLTX or TNXP? Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Is NLTX or TNXP more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Neoleukin Therapeutics' return on equity of -37.22% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Tonix Pharmaceuticals -1,197.86%-163.95%-118.88% SummaryTonix Pharmaceuticals beats Neoleukin Therapeutics on 11 of the 17 factors compared between the two stocks. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.01M$6.58B$5.36B$9.11BDividend YieldN/A2.95%5.13%4.03%P/E Ratio0.009.8389.4717.33Price / Sales5.66307.311,263.57137.15Price / CashN/A61.4443.7535.97Price / Book0.006.055.324.80Net Income-$116.66M$154.62M$122.60M$224.91M7 Day Performance-15.50%-1.68%0.69%1.77%1 Month Performance-29.47%-2.35%1.55%2.22%1 Year Performance-97.42%1.02%27.25%20.67% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals3.1044 of 5 stars$0.24+0.2%$53.50+22,617.6%-97.4%$52.09M$7.77M0.0050Analyst ForecastShort Interest ↑Gap DownNLTXNeoleukin TherapeuticsN/A$19.58-8.9%N/A-41.5%$184.01MN/A-6.3090News CoverageHigh Trading VolumePRQRProQR Therapeutics2.749 of 5 stars$2.23-7.9%$8.83+296.1%-16.8%$182.15M$17.88M-6.97180Short Interest ↑ZNTLZentalis Pharmaceuticals2.8554 of 5 stars$2.55-7.3%$10.00+292.2%-83.3%$181.73M$40.56M-1.02160Short Interest ↓News CoverageCRDFCardiff Oncology2.916 of 5 stars$3.50-3.0%$10.33+195.2%+134.7%$178.97M$688,000.00-3.7220Positive NewsSLNSilence Therapeutics2.72 of 5 stars$5.94-0.8%$57.20+863.0%-71.7%$177.77M$16.25M-3.78100News CoverageCYBNCybin2.6895 of 5 stars$8.87-0.2%$138.00+1,455.8%N/A$177.33MN/A-1.3350News CoveragePositive NewsCGENCompugen2.4179 of 5 stars$1.98+20.7%$4.00+102.0%+19.0%$176.69M$59.85M99.0070High Trading VolumeACRSAclaris Therapeutics3.9782 of 5 stars$2.45-0.8%$11.00+349.0%+117.8%$175.01M$27.08M-4.7186Short Interest ↑GNFTGenfit1.4749 of 5 stars$3.49-3.1%$13.00+272.5%+3.7%$174.49M$76.06M0.00120Short Interest ↑Positive NewsLYELLyell Immunopharma2.2538 of 5 stars$0.59-1.6%$1.00+68.2%-71.2%$173.72M$63,000.00-0.75270 Related Companies and Tools Related Companies Neoleukin Therapeutics Alternatives ProQR Therapeutics Alternatives Zentalis Pharmaceuticals Alternatives Cardiff Oncology Alternatives Silence Therapeutics Alternatives Cybin Alternatives Compugen Alternatives Aclaris Therapeutics Alternatives Genfit Alternatives Lyell Immunopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TNXP) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TNXP Stock Alerts